Drug intelligence / Profile preview

NXE0033744

Development stage: Unknown
Lead developer: Nxera Pharma
Modality: Small Molecules
Administration: Oral

Overview

NXE0033744 is a small molecule, selective prostaglandin EP4 receptor agonist being developed by Nxera Pharma for the treatment of inflammatory bowel disease (IBD), including Crohn's disease. It is administered orally and acts by targeting the prostanoid EP4 receptor.

Targets

PTGER4 (Prostaglandin E2 receptor EP4 subtype)

Beyond the preview

Go deeper on NXE0033744.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NXE0033744.

Explore the full profile